In late May, the National Comprehensive Cancer Network (NCCN) announced updates to two NCCN Clinical Practice Guidelines in Oncology(TM) -- Esophageal Cancer and Gastric Cancer.

The panel added oral fluoropyrimidine, Capecitabine (Xeloda(R), Roche) as an option for treatment of esophageal and gastric cancer due to favorable Phase III trials. The panel also states that capecitabine may replace 5-FU and oxaliplatin may replace cisplatin in triplet regimens for advanced esophageal and gastric cancer.

Additional updates and the NCCN Clinical Practice Guidelines in Oncology(TM) are available at www.nccn.org free of charge.

Hyperthermia therapy with radiation have been added to the 2007 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Breast Cancer as an approved treatment for recurrent breast cancer and other localized cancer recurrences.

According to an explanation by the BSD Medical Treat with Heat website, hyperthermia therapy uses heat, which has been shown to kill cancer cells, in the treatment of cancerous tumors. Hyperthermia therapy also appears to make radiation therapy more effective. "While it has been known for hundreds of years that fevers can kill cancer, only recently has technology been developed that can control and focus heat specifically on tumors. This technology is found in the BSD-500 Hyperthermia System."

The BSD-500 Hyperthermia System is already used in the treatment of skin cancers that are progressive or recurrent despite conventional therapy. To learn more about hyperthermia therapy, request a free information kit, learn treatment options, find a physician, or speak to a patient advisor, visit the Treat with Heat website.